Skip to main content

How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?

Medically reviewed by Judith Stewart, BPharm. Last updated on March 19, 2024.

Official answer

by Drugs.com

Asparlas is given no more frequently than every 21 days and Oncaspar is given no more frequently than every 14 days. Oncaspar is can be given intramuscularly or intravenously while Asparlas is only given intravenously.

Asparlas (calaspargase pegol-mknl) and Oncaspar (pegaspargase) are both forms of PEGylated asparaginase indicated for use in the treatment of acute lymphoblastic leukemia (ALL).

Asparlas provides for a longer interval between doses compared to Oncaspar, and has as an extended shelf life.

Asparlas (calaspargase pegol-mknl) Injection

  • FDA Approved: 2018
  • Dosage Interval: Asparlas is administered intravenously no more frequently than every 21 days.
  • Storage: Store in refrigerator at 2°C to 8°C (36°F to 46°F).
  • Unopened vials may be stored at room temperature (15°C to 25°C [59°F to 77°F]) for no more than 48 hours.

Oncaspar (pegaspargase) Injection

  • FDA Approved: 1994
  • Dosage Interval: Oncaspar is administered intramuscularly or intravenously no more frequently than every 14 days.
  • Storage: Store in refrigerator at 2ºC to 8ºC (36°F to 46°F).

Read next

Related medical questions

Drug information

Related support groups